

Nicholas James

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5896203/publications.pdf>

Version: 2024-02-01

86
papers

13,092
citations

101543

36
h-index

60623

81
g-index

87
all docs

87
docs citations

87
times ranked

10778
citing authors

#	ARTICLE	IF	CITATIONS
1	Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1502-1512.	27.0	5,142
2	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
3	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
4	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	13.7	901
5	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology, The</i> , 2014, 15, 738-746.	10.7	433
6	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016, 17, 243-256.	10.7	361
7	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
8	Homocysteine-Induced Inhibition of Endothelium-Dependent Relaxation in Rabbit Aorta. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 422-427.	2.4	189
9	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
10	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	7.1	155
11	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	1.9	142
12	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	2.8	128
13	Speeding up the Evaluation of New Agents in Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1204-1214.	6.3	126
14	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.	1.6	121
15	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009, 10, 39.	1.6	120
16	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	1.9	117
17	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016, 24, 1167-1174.	2.8	115
18	Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2092.	7.4	108

#	ARTICLE	IF	CITATIONS
19	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009, 103, 464-469.	2.5	86
20	UroMark™ a urinary biomarker assay for the detection of bladder cancer. <i>Clinical Epigenetics</i> , 2017, 9, 8.	4.1	81
21	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
22	Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 555.	7.1	66
23	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. <i>PLoS ONE</i> , 2016, 11, e0149756.	2.5	66
24	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
25	Testing many treatments within a single protocol over 10% years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.	1.6	59
26	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.	1.9	58
27	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	1.9	56
28	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	1.6	54
29	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010, 105, 784-788.	2.5	52
30	Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. <i>European Urology</i> , 2016, 70, 906-908.	1.9	51
31	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
32	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	1.9	48
33	Targeted deep sequencing of urothelial bladder cancers and associated urinary <i>scp</i> DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. <i>BJU International</i> , 2019, 124, 532-544.	2.5	47
34	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.	1.6	42
35	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228A/T Mutation. <i>Bladder Cancer</i> , 2018, 4, 41-48.	0.4	40
36	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40

#	ARTICLE	IF	CITATIONS
37	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 294-301.	5.4	38
38	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019, 20, 294.	1.6	37
39	A comparison of patient and tumour characteristics in two <scp>UK</scp> bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013, 112, 169-175.	2.5	35
40	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
41	Survey of the Impact of COVID-19 on Oncologistsâ€™ Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1248-1257.	1.8	33
42	Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 338.e1-338.e7.	1.6	32
43	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
44	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. <i>Scientific Reports</i> , 2018, 8, 11290.	3.3	28
45	Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 298-298.	1.6	27
46	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021, 79, 307-315.	1.9	20
47	Biology of testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1659-1673.	2.4	19
48	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
49	Defining Bowel Dose Volume Constraints for Bladder Radiotherapy Treatment Planning. <i>Clinical Oncology</i> , 2015, 27, 22-29.	1.4	18
50	Health-related quality of life around the time of diagnosis in patients with bladder cancer. <i>BJU International</i> , 2019, 124, 984-991.	2.5	16
51	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 650-658.	10.7	16
52	Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. <i>BJU International</i> , 2018, 121, 680-683.	2.5	15
53	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 280-280.	1.6	15
54	CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. <i>Scientific Reports</i> , 2020, 10, 342.	3.3	13

#	ARTICLE	IF	CITATIONS
55	Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. <i>Oncotarget</i> , 2018, 9, 25244-25253.	1.8	12
56	Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. <i>European Urology Oncology</i> , 2023, 6, 67-75.	5.4	12
57	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. <i>Frontiers in Oncology</i> , 2020, 10, 812.	2.8	11
58	Flexible trial design in practice â€“ dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011, 12, .	1.6	10
59	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015, 1, 82-89.	3.1	10
60	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2019, 5, 263-272.	0.4	10
61	Endocrine therapy and other targeted therapies for metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1179-1195.	2.4	9
62	A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research. <i>Medical Decision Making</i> , 2016, 36, 321-334.	2.4	9
63	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDEâ€™s â€œM1 RT Comparisonâ€. <i>European Urology Oncology</i> , 2020, 3, 412-419.	5.4	9
64	Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. <i>Anticancer Research</i> , 2015, 35, 1057-63.	1.1	9
65	Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. <i>Drug Design, Development and Therapy</i> , 2014, 9, 13.	4.3	8
66	Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently. <i>European Urology Focus</i> , 2019, 5, 119-122.	3.1	8
67	Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team. <i>JMIR Research Protocols</i> , 2017, 6, e147.	1.0	7
68	STAMPEDE trial and patients with non-metastatic prostate cancer â€“ Authors' reply. <i>Lancet</i> , The, 2016, 388, 235-236.	13.7	6
69	Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2016, 34, 162-162.	1.6	6
70	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA5003-LBA5003.	1.6	6
71	Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 162-162.	1.6	5
72	Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. <i>Genome Medicine</i> , 2022, 14, .	8.2	5

#	ARTICLE	IF	CITATIONS
73	Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5030-5030.	1.6	4
74	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	2.5	4
75	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	3.8	3
76	Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. <i>BJU International</i> , 2021, , .	2.5	3
77	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	12.8	3
78	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA5003-LBA5003.	1.6	2
79	Prognostic and predictive models in hormone-sensitive prostate cancer. <i>BJU International</i> , 2018, 122, 352-353.	2.5	1
80	Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 440-440.	1.6	1
81	Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level.. <i>Journal of Clinical Oncology</i> , 2017, 35, 292-292.	1.6	1
82	Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. <i>Eur Urol</i> 2016;70:707-708. <i>European Urology</i> , 2017, 72, e17.	1.9	0
83	Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>Eur Urol</i> 2020;77:260-8. <i>European Urology</i> , 2020, 77, e156-e157.	1.9	0
84	Reply to Santhanam Sundar and Paul Symonds's Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-15. <i>European Urology</i> , 2021, 80, e51-e52.	1.9	0
85	Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 461-461.	1.6	0
86	Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway. <i>BJU International</i> , 2022, 129, 691-694.	2.5	0